Anemia News and Research RSS Feed - Anemia News and Research

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Changes in use of anemia drugs affects risk of death or cardiovascular events in dialysis patients

Changes in use of anemia drugs affects risk of death or cardiovascular events in dialysis patients

A new study examines whether recent changes in the use of anemia drugs for patients on dialysis have contributed to changes in rates of death or cardiovascular events. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology, indicate that these risks appear to be decreasing for patients on dialysis as well as for older adults (Medicare beneficiaries) who are not on dialysis. [More]
Kansas State researchers develop 3-D printed device that quickly detect anemia from blood

Kansas State researchers develop 3-D printed device that quickly detect anemia from blood

Identifying a blood disorder may be as easy as running a blood sample from a finger prick under a smartphone. That is the concept behind a new biomedical device being developed by Kansas State University researchers. [More]
Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. [More]
Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA). [More]
New anti-ageing therapy may be effective against aplastic anaemia

New anti-ageing therapy may be effective against aplastic anaemia

Aplastic anaemia is a rare, and potentially fatal, disease of the blood, by which the bone marrow is unable to generate blood cells at the appropriate pace. Many forms of aplastic anaemia share an important link with the ageing process: the shortening of telomeres, structures that protect the ends of chromosomes. [More]
New definitions and clinical criteria for sepsis, septic shock

New definitions and clinical criteria for sepsis, septic shock

Clifford S. Deutschman, MS, MD, vice chair of research in the Department of Pediatrics at Cohen Children's Medical Center and an investigator at The Feinstein Institute for Medical Research , presented new definitions and clinical criteria for sepsis and septic shock at the Society of Critical Care Medicine's 45th Critical Care Congress in Orlando, FL. [More]
Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. [More]
Maternal supplementation with docosahexaenoic acid improves fetal iron metabolism

Maternal supplementation with docosahexaenoic acid improves fetal iron metabolism

A research has proven, for the first time, that maternal supplementation with docosahexaenoic acid (DHA), an omega-3 essential polyunsaturated fatty acid, enhances fetal iron metabolism thanks to a greater expression of key genes regulating its transfer through the placenta. [More]
Testosterone treatment for older men improves sexual function, walking ability and mood

Testosterone treatment for older men improves sexual function, walking ability and mood

As men age, their testosterone levels decrease, but prior studies of the effects of administering testosterone to older men have been inconclusive. Now, research shows that testosterone treatment for men over 65 improves sexual function, walking ability and mood, according to a study published in the New England Journal of Medicine by team researchers from the Perelman School of Medicine at the University of Pennsylvania, and twelve other medical centers in the United States, in partnership with the National Institute on Aging. [More]
MemorialCare partners with Fresenius Medical Care to operate 15 dialysis clinics in Southern California

MemorialCare partners with Fresenius Medical Care to operate 15 dialysis clinics in Southern California

MemorialCare Health System announced today that it has entered into a joint venture partnership with Fresenius Medical Care North America to operate 15 dialysis clinics in Orange and Los Angeles counties. Thirteen of these clinics are fully operational and two additional clinics are being developed in San Juan Capistrano and Huntington Beach. [More]
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil). [More]
Yale Cancer Center researchers identify cause of myeloma

Yale Cancer Center researchers identify cause of myeloma

Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published in the Feb. 11 issue of the New England Journal of Medicine, could fundamentally change the way this cancer and others are treated. [More]
2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

A first-ever interlaboratory study of four versions of a therapeutic protein drug—all manufactured from living cells—reports that an established analytical tool akin to magnetic resonance imaging reliably assessed the atomic structures of the biologically similar products, yielding the equivalent of a fingerprint for each. [More]
Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. [More]
Three Case Western faculty members receive funding to develop new diagnostic technologies

Three Case Western faculty members receive funding to develop new diagnostic technologies

Three Case Western Reserve University faculty members have received funding to further develop emerging technologies aimed at malaria, cystic fibrosis, and sickle cell anemia. [More]
Nearly 3.3 million children in U.S. have dizziness or balance problem

Nearly 3.3 million children in U.S. have dizziness or balance problem

More than 1 in 20 (nearly 3.3 million) children between the ages of 3 and 17 have a dizziness or balance problem, according to an analysis of the first large-scale, nationally representative survey of these problems in U.S. children. [More]
Colorectal cancer in younger patients associated with more advanced disease but better survival

Colorectal cancer in younger patients associated with more advanced disease but better survival

Nearly 15 percent of patients diagnosed with colorectal cancer were younger than 50, the age at which screening recommendations begin. [More]
Simple blood test could help eliminate B12 deficiencies among older adults in long-term care homes

Simple blood test could help eliminate B12 deficiencies among older adults in long-term care homes

A high proportion of older adults entering long-term care homes in Ontario are B12 deficient, with more developing deficiencies over the course of their first year in residence, according to research from the University of Waterloo. There is a connection between B12 deficiency and several serious health conditions. [More]
Mylan releases generic version of Felbatol Tablets in U.S.

Mylan releases generic version of Felbatol Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Felbamate Tablets USP, 400 mg and 600 mg, which is the generic version of Meda Pharms' Felbatol Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product. [More]
Advertisement
Advertisement